医学
吉西他滨
养生
中性粒细胞减少症
内科学
耐受性
白细胞减少症
乳腺癌
三阴性乳腺癌
肿瘤科
化疗
胃肠病学
转移性乳腺癌
顺铂
人口
外科
癌症
不利影响
环境卫生
作者
Çiğdem Erten,Lütfiye Demir,İşıl Somali,Ahmet Alacacıoğlu,Yüksel Küçükzeybek,Murat Akyol,Alper Can,Ahmet Dirican,Vedat Bayoğlu,Mustafa Oktay Tarhan
标识
DOI:10.7314/apjcp.2013.14.6.3711
摘要
Background: To assess the efficacy and tolerability of Cisplatin plus Gemcitabine combination in patients with brain metastases (BM) from breast cancer (BC). Materials and Methods: Eighteen BC patients with BM who were treated with Cisplatin plus Gemcitabine regimen between 2003-2011 were evaluated. Results: A median of 6 cycles of this regimen were received, in fifteen patients (83.3%) as first-line chemotherapy, in 2 as second-line and in 1 as third-line after diagnosis of BM. Dose reduction was performed in 11 (61.1%) patients; major reasons were neutropenia and leukopenia. Grade III neutropenia and Grade II trombocytopenia rates were 33.3% and 16.7% respectively. Overall response rate (ORR; complete+partial response rate) was 33.4% (n=6) for the entire study population; triple negative patients achieved an 66.6% ORR while hormone receptor (HR) positive patients had 25% and HER2 positive patients 12.5%. Median progression-free survival was 5.6 months (2.4-8.8 months, 95%CI) and longer in patients with triple negative breast cancer (TNBC) (median 7.4 months, 95%CI, 2.4-12.3 months) than the patients with other subtypes (median 5 months for HER2 positive and 3.6 months for HR positive patients). Median PFS of the patients with TNBC who received this regimen as first-line was 9.2 months (5.2-13.2 months, 95%CI). Conclusions: Cisplatin plus Gemcitabine may be a treatment option for patients with BM from breast cancer. Longer PFS and higher response rates are results that support the usage of this regimen especially for the triple negative subtype. However, further prospective and randomized trials are clearly required to provide more exact information.
科研通智能强力驱动
Strongly Powered by AbleSci AI